Antibe Therapeutics CEO and leadership

John L. Wallace (born September 25, 1956) is a medical scientist and was the founder of the Inflammation Research Network at The University of Calgary and inaugural director of the Farncombe Institute at McMaster University. In November 2013, he became the tenth recipient of the Heymans Foundation Memorial Medal. Since its inauguration in 1972, the Medal had been awarded twelve times; six of the recipients are Nobel Laureates. Wallace is also the 2009 recipient of the Premier's Summit Award in Innovation, Canada's largest value research award (C$5 million) aimed at supporting the work of an individual scientist.

Alain Wilson is a Chief Financial Officer at Antibe Therapeutics. He works or has worked as VP/Head:Toronto Office at Oliver Wyman and Partner at Revelstoke Equity Inc. Alain attended Queen's University and IMD business school.

Dan is CEO of Antibe Therapeutics, a publicly-traded bio-pharmaceutical company based in Toronto, Canada. Antibe aims to revolutionize the treatment of inflammation and pain across a range of chronic diseases.

In addition, Dan maintains several advisory and governance roles. He is board member and former chair of the strategic planning and governance committees of Green Shield Canada, a leader in health benefits administration. As board member for Save the Children International, Dan launched the audit committee and acted as treasurer until 2007. Operating in 120 countries, Save the Children International's 30 national organizations comprise the world's foremost charity dedicated to children's rights.

Although educated as a corporate lawyer, Dan began his career in the Canadian Armed Forces as a rescue pilot. Following his military service, Dan’s career has centred on managing senior teams and raising financing for ventures moving from concept to market entry.

A member of the bar in both Ontario and New York State, Dan earned his JD at Queen’s University and articled at Stikeman Elliott. He is fluent in French and English.

David Vaughan is a Chief Development Officer at Antibe Therapeutics and Chief Development Officer at Antibe Holdings Inc. He has worked as Head:Anti-Infectives Product Dev at Bayer. David attended University of Toronto.

An anesthesiologist, Dr. Stauffer has served as CMO in public and private drug therapy companies for nearly 20 years, building teams of physicians, scientists, regulators and safety experts to drive clinical success for a number of chronic and acute pain assets. Dr. Stauffer will assume a leadership role in Antibe’s clinical development strategy and its increasing engagement with global regulatory agencies and potential large-market partners.

Following his medical training, Dr. Stauffer practiced frontline medicine for a decade, including eight years as a US Navy general practice physician. He then joined the US Food and Drug Administration (“FDA”) as a Medical Review Officer for anti-inflammatory and analgesic drugs, subsequently being recruited by Abbott Laboratories as Global Medical Director. Over the succeeding years, Dr. Stauffer led clinical operations, regulatory and medical affairs teams at Alpharma and Ikaria, each of which was acquired in $1.6 billion cash transactions. He was also instrumental in guiding the clinical development programs that underpinned equity raises totaling more than $250 million for Cara Therapeutics, a developer of novel chemical entities to treat post-operative pain and chronic itch in Chronic Kidney Disease.

Dr. Stauffer earned his medical degree from the Philadelphia College of Osteopathic Medicine and completed his anesthesiology residency at Johns Hopkins University Hospital, where he maintained a part-time Assistant Professorship until 2016. He earned his MBA degree in a joint program at New York University, the London School of Economics in the UK, and the Hautes Etudes Commerciales management school in Paris, France. Dr. Stauffer is a founding member of the Initiative on Methods, Measurement and Pain Assessment in Clinical Trials (“IMMPACT”), which became an official public-private partnership among pharmaceutical companies, the FDA, the National Institutes of Health, academia and patient advocacy organizations across the USA.

John L. Wallace (born September 25, 1956) is a medical scientist and was the founder of the Inflammation Research Network at The University of Calgary and inaugural director of the Farncombe Institute at McMaster University. In November 2013, he became the tenth recipient of the Heymans Foundation Memorial Medal. Since its inauguration in 1972, the Medal had been awarded twelve times; six of the recipients are Nobel Laureates. Wallace is also the 2009 recipient of the Premier's Summit Award in Innovation, Canada's largest value research award (C$5 million) aimed at supporting the work of an individual scientist.

John L. Wallace (born September 25, 1956) is a medical scientist and was the founder of the Inflammation Research Network at The University of Calgary and inaugural director of the Farncombe Institute at McMaster University. In November 2013, he became the tenth recipient of the Heymans Foundation Memorial Medal. Since its inauguration in 1972, the Medal had been awarded twelve times; six of the recipients are Nobel Laureates. Wallace is also the 2009 recipient of the Premier's Summit Award in Innovation, Canada's largest value research award (C$5 million) aimed at supporting the work of an individual scientist.

Dan is CEO of Antibe Therapeutics, a publicly-traded bio-pharmaceutical company based in Toronto, Canada. Antibe aims to revolutionize the treatment of inflammation and pain across a range of chronic diseases.

In addition, Dan maintains several advisory and governance roles. He is board member and former chair of the strategic planning and governance committees of Green Shield Canada, a leader in health benefits administration. As board member for Save the Children International, Dan launched the audit committee and acted as treasurer until 2007. Operating in 120 countries, Save the Children International's 30 national organizations comprise the world's foremost charity dedicated to children's rights.

Although educated as a corporate lawyer, Dan began his career in the Canadian Armed Forces as a rescue pilot. Following his military service, Dan’s career has centred on managing senior teams and raising financing for ventures moving from concept to market entry.

A member of the bar in both Ontario and New York State, Dan earned his JD at Queen’s University and articled at Stikeman Elliott. He is fluent in French and English.